Richard Daniell - 09 Dec 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Exec. VP, European Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell
Issuer symbol
TEVA
Transactions as of
09 Dec 2025
Net transactions value
-$1,186,584
Form type
4
Filing time
11 Dec 2025, 16:09:26 UTC
Previous filing
07 Mar 2025
Next filing
29 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Daniell Richard Exec. VP, European Commercial C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 11 Dec 2025 0001726096

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise $1,869,505 +100,457 +208% $18.61 148,841 09 Dec 2025 Direct F1
transaction TEVA Ordinary Shares Options Exercise $255,037 +15,011 +10% $16.99 163,852 09 Dec 2025 Direct F1
transaction TEVA Ordinary Shares Sale $3,311,126 -115,468 -70% $28.68 48,384 09 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Stock Options (right to buy) Options Exercise $0 -100,457 -100% $0.000000 0 09 Dec 2025 Ordinary Shares 100,457 $18.61 Direct F1, F3
transaction TEVA Stock Options (right to buy) Options Exercise $0 -15,011 -100% $0.000000 0 09 Dec 2025 Ordinary Shares 15,011 $16.99 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.635 to $28.765, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Stock options were granted on February 9, 2018, with 33,485 vested on each of February 9, 2020 and February 9, 2021, and 33,487 vested on February 9, 2022.
F4 Stock options were granted on September 18, 2017, with 7,505 vested on September 18, 2018, and 7,506 vested on September 18, 2019.